Literature DB >> 15962928

Bioactivation of 2,3-diaminopyridine-containing bradykinin B1 receptor antagonists: irreversible binding to liver microsomal proteins and formation of glutathione conjugates.

Cuyue Tang1, Raju Subramanian, Yuhsin Kuo, Sergey Krymgold, Ping Lu, Scott D Kuduk, Christina Ng, Dong-Mei Feng, Chad Elmore, Eric Soli, Jonathan Ho, Mark G Bock, Thomas A Baillie, Thomayant Prueksaritanont.   

Abstract

The 2,3-diaminopyridine (DAP) moiety was found to represent a core structure essential for the potency of a new series of human bradykinin B(1) receptor antagonists. However, incubation of (14)C-labeled 2,3-DAP derivatives with rat and human liver microsomes resulted in substantial irreversible binding of radioactive material to macromolecules by a process that was NADPH-dependent. Trapping the reactive species with GSH led to significant reduction of the irreversible binding of radioactivity, with concomitant formation of abundant GSH adducts. One type of thiol adducts (detected in both human and rat liver microsomes), resulting from addition of 305 Da to the parent compound, was observed with all 2,3-DAP compounds. These adducts also were detected in rat hepatocyte incubates, as well as in rat bile, following intravenous administration of 2,3-DAPs. Formation of the conjugates appeared to involve modification of the DAP ring, based upon mass spectral analysis of a number of representative GSH adducts; this was corroborated by detailed LC NMR analysis of one compound. Formation of this type of GSH conjugate was markedly reduced when the 2-amino methyl group linking the 2,3-DAP and the biphenyl moiety was replaced with an ether oxygen atom. It is postulated, therefore, that oxidation of the 2-amino group serves as a key step leading to the formation of reactive species associated with the DAP core. In addition, this step appears to be mediated primarily by P450 3A, as evidenced by the marked decrease in both the irreversible binding of radioactivity and the formation of the GSH adducts in human liver microsomes following treatment with ketoconazole and monoclonal antibodies against P450 3A. A mechanism for the bioactivation of 2,3-DAP is proposed wherein oxidation (dehydrogenation or N-hydroxylation followed by dehydration) of the 2-amino group, catalyzed by P450 3A, results in the formation of a highly electrophilic species, pyridine-2,3-diimine.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15962928     DOI: 10.1021/tx0500427

Source DB:  PubMed          Journal:  Chem Res Toxicol        ISSN: 0893-228X            Impact factor:   3.739


  3 in total

1.  Discovery of 4,4-Disubstituted Quinazolin-2-ones as T-Type Calcium Channel Antagonists.

Authors:  James C Barrow; Kenneth E Rittle; Thomas S Reger; Zhi-Qiang Yang; Phung Bondiskey; Georgia B McGaughey; Mark G Bock; George D Hartman; Cuyue Tang; Jeanine Ballard; Yuhsin Kuo; Thomayant Prueksaritanont; Cindy E Nuss; Scott M Doran; Steven V Fox; Susan L Garson; Richard L Kraus; Yuxing Li; Michael J Marino; Valerie Kuzmick Graufelds; Victor N Uebele; John J Renger
Journal:  ACS Med Chem Lett       Date:  2010-02-01       Impact factor: 4.345

2.  Short-acting T-type calcium channel antagonists significantly modify sleep architecture in rodents.

Authors:  Zhi-Qiang Yang; Kelly-Ann S Schlegel; Youheng Shu; Thomas S Reger; Rowena Cube; Christa Mattern; Paul J Coleman; Jim Small; George D Hartman; Jeanine Ballard; Cuyue Tang; Yuhsin Kuo; Thomayant Prueksaritanont; Cindy E Nuss; Scott Doran; Steve V Fox; Susan L Garson; Yuxing Li; Richard L Kraus; Victor N Uebele; Adekemi B Taylor; Wei Zeng; Wei Fang; Cynthia Chavez-Eng; Matthew D Troyer; Julie Ann Luk; Tine Laethem; William O Cook; John J Renger; James C Barrow
Journal:  ACS Med Chem Lett       Date:  2010-08-24       Impact factor: 4.345

3.  Stereoselective flunoxaprofen-S-acyl-glutathione thioester formation mediated by acyl-CoA formation in rat hepatocytes.

Authors:  Mark P Grillo; Jill C M Wait; Michelle Tadano Lohr; Smriti Khera; Leslie Z Benet
Journal:  Drug Metab Dispos       Date:  2010-01       Impact factor: 3.922

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.